Overview Recently Resected Patient Extending Adjuvant GLIVEC Recurrence Post Adjuvant Therapy Metastatic Patient With Progression After GI/Surgeon Diagnosis About GIST Expert Opinions
Print
Font size:

EXTENDING ADJUVANT GLIVEC

Post Adjuvant Therapy/Index
60 years old
14 months since diagnosis
12 months on therapy
Duodenal GIST
Original tumor: 7 cm
Mitotic rate: ≤5/50 HPFs
34% RISK OF RECURRENCE1

KIT+ gastrointestinal stromal tumor (GIST) patients on adjuvant GLIVEC (imatinib) may start to question the need to continue therapy. They need to know:

  • In a pre-GLIVEC study, resected GIST patients had a 54% survival rate at 5 years2
    • Once GIST recurs, the patient is considered metastatic and the chance of cure is extremely low3
  • GLIVEC, the only approved adjuvant treatment for KIT+ GIST, is proven to reduce risk of recurrence in 2 Phase 3 randomized clinical trials4,5
  • Clinical data now demonstrate that adjuvant treatment, with 3 years of GLIVEC provides a significant benefit vs 1 year in both recurrence-free survival (RFS) and overall survival (OS) at 5 years5
  • Updated National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) guidelines support the use of adjuvant GLIVEC for at least 36 months in appropriate KIT+ GIST patients3

See how longer GLIVEC adjuvant treatment may help KIT+ GIST patients reduce their risk of recurrence.5

Historical Risk of GIST Recurrence

3 Years vs 1 Year Adjuvant Study Design

GLIVEC Efficacy

New Tablet
and Packaging

Learn more

Read about the latest clinical
trial proving the benefits of 3 years of adjuvant GLIVEC

Prescribing
GLIVEC

Learn more

GLIVEC Product
Characteristics

View more

GLIVEC Safety
and Tolerability

Learn more

GLIVEC and KIT+ GIST

Glivec and Ph+ CML

Glivec and Additional Indications

For Your Patients

Library and Tools